UNSPSC 51361933: Butalbital sodium

This classification denotes a barbiturate with the molecular formula C11H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BBH31P2ABJ, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-, monosodium salt but more generally known as butalbital sodium, which bears US NIH Compound Identifier 6464. European Medicines Agency schedules Butalbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00910MIG.

Most nations, for tariff and trade purposes, schedule butalbital sodium under HS 29335390 and SITC 51576. As of Q4 2014, BUTALBITAL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)CC1(C(=O)NC(=O)[N-]C1=O)CC=C.[NA+].

UNSPSC 51361933 Butalbital sodium is a Commodity code that nominally identifies a barbiturate pharmaceutical product, but recent state and local opportunities tagged under this code do not reflect procurement of butalbital sodium itself. Instead, the code appears to have been applied to broader pharmaceutical and health-related product solicitations, creating a significant scope mismatch. State and local governments soliciting under this code are pursuing naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and direct-to-manufacturer prescription program capabilities. The issuing bodies include county health agencies, state health and human services departments, and multistate cooperative purchasing alliances. This code shows limited relevance to the specific pharmaceutical it nominally identifies, and business development professionals should verify the actual product or service scope before responding to opportunities tagged with it.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due by July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) posted in January 2026 with responses due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities in Minnesota and Oregon. The MMCAP procurement requires cGMP certification, DSCSA compliance, and contracting relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026.